What is it about?

Existing drugs to treat adrenocortical carcinoma have low efficacy and cause significant adverse effects. We describe the molecular and cellular mechanisms of a prospective agent for the treatment of adrenocortical carcinoma designated ATR-101.

Featured Image

Read the Original

This page is a summary of: ATR‐101 inhibits cholesterol efflux and cortisol secretion by ATP‐binding cassette transporters, causing cytotoxic cholesterol accumulation in adrenocortical carcinoma cells, British Journal of Pharmacology, August 2017, Wiley,
DOI: 10.1111/bph.13951.
You can read the full text:

Read

Contributors

Be the first to contribute to this page